Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 41

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 41
---
138 |     |         | 192,807 |     |         | 109,468 |     |       | 485,413 |
| Liabilities:                                                                |     |                |         |     |         |         |     |         |         |     |       |         |
| Financial liabilities measured at fair value through profit or loss         |     |                |         |     |         |         |     |         |         |     |       |         |
| Derivatives                                                                 |     |                |       — |     |         |   1,568 |     |         |   9,210 |     |       |  10,778 |
| Financial liabilities associated with contingent consideration arrangements |     |                |       — |     |         |       — |     |         |   3,145 |     |       |   3,145 |
| Derivatives for which hedge accounting is applied                           |     |                |       — |     |         |  25,319 |     |         |       — |     |       |  25,319 |
| Total                                                                       |     |                |       — |     |         |  26,887 |     |         |  12,355 |     |       |  39,242 |

(2) Valuation Techniques

The fair value of derivatives classified as Level 2 is measured based on Treasury management system valuation models or the Black-Scholes model, whose significant inputs are based on observable market data.

Derivatives classified as Level 3 include those recognized in connection with settlements of cash flows arising from differences between the fixed prices and floating market prices of renewable energy in a virtual power purchase agreement and those recognized in an agreement to offset the volatility of such cash flows. The fair value of derivatives in Level 3 is measured using the discounted cash flow method. The key assumptions taken into account include forecasted renewable energy prices and the expected generation of the renewable energy generating facility.

The fair value of the investment in convertible notes is measured using techniques such as the discounted cash flow and option pricing models.

The fair value of trade and other receivables, which are due from customers that Takeda has the option to factor, are measured based on the invoiced amount.

Equity instruments and investments in debt instruments are not held for trading. If equity instruments or investments in debt instruments are quoted in an active market, the fair value is based on price quotations at the period-end-date. If equity instruments